Emerging Infectious Disease ISSN: 1080-6059

Demand for Prophylaxis after Bioterrorism-Related Anthrax Cases, 2001

Edward A. Belongia*

, Burney Kieke*, Ruth Lynfield†, Jeffrey P. Davis‡, and Richard E. Besser§

Author affiliations: *Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA; †Minnesota Department of Health, Minneapolis, Minnesota, USA; ‡Wisconsin Division of Public Health, Madison, Wisconsin, USA; §Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure 1

A) Actual and predicted fluoroquinolone prescriptions, January 2000 through December 2002. B) Actual and predicted fluoroquinolone prescriptions as a percentage of all outpatient antibiotic prescriptions, January 2000 through December 2002. Tetracycline and related antimicrobial agents were excluded from the denominator in each month. Vertical bars show 95% confidence intervals. All models included categorical effects for year and month and indicator variables for October, November, and December

Figure 1. A) Actual and predicted fluoroquinolone prescriptions, January 2000 through December 2002. B) Actual and predicted fluoroquinolone prescriptions as a percentage of all outpatient antibiotic prescriptions, January 2000 through December 2002. Tetracycline and related antimicrobial agents were excluded from the denominator in each month. Vertical bars show 95% confidence intervals. All models included categorical effects for year and month and indicator variables for October, November, and December, 2001

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.